NASDAQ:AMRN - Amarin Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $4.38
Forecasted Upside: 203.82 %
Number of Analysts: 6
Breakdown:
2 Sell Ratings
3 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$1.44 As of 05/27/2022 01:00 AM ET

▲ +0.01 (0.70%)

1 month | 3 months | 12 months

Get New Amarin Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AMRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMRN

^$4.38

▲ +203.82% Upside Potential

This price target is based on 6 analysts offering 12 month price targets for Amarin in the last 3 months. The average price target is $4.38, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 203.82% upside from the last price of $1.44.

Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Amarin. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

12/4/2020

0 strong buy ratings
5 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

3/4/2021

0 strong buy ratings
2 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

6/2/2021

0 strong buy ratings
2 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

8/31/2021

0 strong buy ratings
2 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

11/29/2021

0 strong buy ratings
1 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

2/27/2022

0 strong buy ratings
1 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

4/28/2022

0 strong buy ratings
1 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

5/28/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/24/2022	The Goldman Sachs Group	Lower Price Target	Sell	$1.75 ➝ $1.50	Medium
5/6/2022	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		Medium
5/5/2022	HC Wainwright	Downgrade	Buy ➝ Neutral	$10.00 ➝ $3.00	High
5/5/2022	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$10.00 ➝ $3.00	High
5/4/2022	Northland Securities	Downgrade	Outperform ➝ Market Perform		High
3/2/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		Medium
2/16/2022	SVB Leerink	Lower Price Target	Outperform	$11.00 ➝ $10.00	Medium
1/31/2022	SVB Leerink	Lower Price Target	Outperform	$12.00 ➝ $11.00	Low
9/26/2021	SVB Leerink	Reiterated Rating	Buy	$12.00	Low
9/9/2021	SVB Leerink	Initiated Coverage	Outperform	$12.00	Low
8/9/2021	HC Wainwright	Reiterated Rating	Buy	$10.00	Medium
6/11/2021	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	Medium
5/18/2021	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Sell	$6.00 ➝ $5.00	Medium
5/12/2021	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$6.00 ➝ $5.00	High
2/1/2021	SVB Leerink	Boost Price Target	Outperform	$12.00 ➝ $16.00	Low
2/1/2021	HC Wainwright	Reiterated Rating	Buy		Low
1/8/2021	Piper Sandler	Reiterated Rating	Overweight	$19.00	Low
12/23/2020	The Goldman Sachs Group	Lower Price Target		$8.00 ➝ $6.00	N/A
12/7/2020	Smith Barney Citigroup	Lower Price Target		$12.00 ➝ $7.00	Low
9/29/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		Low
9/28/2020	SVB Leerink	Boost Price Target	Outperform ➝ Outperform	$9.00 ➝ $12.00	Medium
9/8/2020	Cantor Fitzgerald	Lower Price Target		$35.00 ➝ $15.00	Medium
9/3/2020	Stifel Nicolaus	Lower Price Target	Hold	$8.00 ➝ $5.00	High
8/25/2020	Piper Sandler	Initiated Coverage	Overweight	$21.00	High
8/5/2020	HC Wainwright	Reiterated Rating	Buy		Medium
8/4/2020	Stifel Nicolaus	Reiterated Rating	Hold	$8.00	Medium
6/16/2020	Stifel Nicolaus	Reiterated Rating	Hold		High
6/15/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	Low
6/3/2020	Oppenheimer	Reiterated Rating	Hold		Medium
5/22/2020	Cowen	Reiterated Rating	Buy	$10.00	N/A
5/5/2020	Northland Securities	Initiated Coverage	Outperform	$15.00	Medium
5/4/2020	Aegis	Boost Price Target	Buy	$9.00 ➝ $11.00	Medium
5/4/2020	SVB Leerink	Boost Price Target	Outperform	$7.00 ➝ $9.00	High
5/1/2020	Citigroup	Boost Price Target	Buy	$6.00 ➝ $12.00	Low
5/1/2020	HC Wainwright	Reiterated Rating	Buy		Low
4/30/2020	Stifel Nicolaus	Reiterated Rating	Hold	$8.00	Low
4/14/2020	Cowen	Boost Price Target		$8.00 ➝ $10.00	High
4/13/2020	Stifel Nicolaus	Reiterated Rating	Hold		High
4/2/2020	HC Wainwright	Reiterated Rating	Buy	$51.00	Medium
4/1/2020	Citigroup	Lower Price Target	Buy	$24.00 ➝ $6.00	High
3/31/2020	Stifel Nicolaus	Lower Price Target	Hold	$24.00 ➝ $8.00	High
3/31/2020	Oppenheimer	Upgrade	Underperform ➝ Market Perform		High
3/31/2020	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$27.00 ➝ $4.00	High
3/31/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$30.00 ➝ $4.00	High
3/13/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$11.50 ➝ $28.00	Medium
3/2/2020	Cowen	Initiated Coverage	Outperform	$23.00	High
2/27/2020	Stifel Nicolaus	Reiterated Rating	Hold	$24.00	High
2/26/2020	Oppenheimer	Lower Price Target	Underperform	$13.00 ➝ $12.00	High
2/26/2020	HC Wainwright	Reiterated Rating	Buy ➝ Positive	$51.00	High
2/18/2020	Citigroup	Upgrade	Neutral ➝ Buy	$27.00 ➝ $24.00	Medium
1/22/2020	Oppenheimer	Reiterated Rating	Sell	$8.00 ➝ $13.00	Low
1/14/2020	Jefferies Financial Group	Reiterated Rating	Buy	$30.00	Low
1/9/2020	HC Wainwright	Reiterated Rating	Buy	$51.00	High
1/7/2020	Stifel Nicolaus	Reiterated Rating	Hold		High
1/6/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral	$22.00	N/A
1/2/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	High
12/20/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	Low
12/16/2019	Oppenheimer	Boost Price Target	Underperform	$7.00 ➝ $8.00	High
12/16/2019	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$26.00 ➝ $28.00	High
12/13/2019	SVB Leerink	Reiterated Rating	Buy	$29.00	High
12/3/2019	Roth Capital	Reiterated Rating	Buy	$31.00	High
12/2/2019	SVB Leerink	Reiterated Rating	Buy	$29.00	Low
12/2/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	Low
11/29/2019	Jefferies Financial Group	Reiterated Rating	Buy	$30.00	Low
11/27/2019	Citigroup	Downgrade	Buy ➝ Neutral		Low
11/19/2019	Oppenheimer	Initiated Coverage	Underperform	$7.00 ➝ $7.00	High
11/18/2019	Citigroup	Downgrade	Buy ➝ Neutral	$23.00 ➝ $27.00	High
11/15/2019	SVB Leerink	Boost Price Target		$28.00 ➝ $29.00	Low
11/13/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	Low
11/12/2019	Stifel Nicolaus	Reiterated Rating	Buy		High
11/6/2019	HC Wainwright	Reiterated Rating	Buy		Low
10/31/2019	Aegis	Initiated Coverage	Buy	$23.00	Low
10/17/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Low
10/15/2019	The Goldman Sachs Group	Initiated Coverage	Neutral	$17.00	Medium
9/12/2019	Jefferies Financial Group	Set Price Target	Buy	$30.00	Medium
9/10/2019	SVB Leerink	Set Price Target	Buy	$26.00	Low
9/6/2019	Roth Capital	Set Price Target	Buy	$31.00	Medium
9/3/2019	Jefferies Financial Group	Set Price Target	Buy	$30.00	Low
9/3/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Low
8/21/2019	Roth Capital	Set Price Target	Buy	$31.00	Medium
8/14/2019	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$26.00	Medium
8/9/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	N/A
8/1/2019	HC Wainwright	Reiterated Rating	Buy		High
7/31/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	High
7/31/2019	Stifel Nicolaus	Reiterated Rating	Buy	$26.00	High
7/11/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Medium
7/9/2019	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$30.00	Low
7/3/2019	HC Wainwright	Set Price Target	Buy	$51.00	Low
7/2/2019	Stifel Nicolaus	Set Price Target	Buy	$27.00	High
7/2/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	High
6/26/2019	HC Wainwright	Set Price Target	Buy	$51.00	Medium
6/17/2019	Roth Capital	Initiated Coverage	Buy	$31.00	Medium
4/1/2019	HC Wainwright	Reiterated Rating	Buy		Medium
3/21/2019	Stifel Nicolaus	Initiated Coverage	Buy ➝ Buy	$27.00	High
1/17/2019	HC Wainwright	Reiterated Rating	Buy	$51.00	Low
1/8/2019	Citigroup	Lower Price Target		$20.00	Low
1/7/2019	SunTrust Banks	Reiterated Rating	Buy		High
12/28/2018	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Medium
12/21/2018	Cantor Fitzgerald	Set Price Target	Buy	$35.00	High
12/20/2018	Jefferies Financial Group	Set Price Target	Buy	$30.00	High
12/14/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	Medium
12/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	High
11/12/2018	HC Wainwright	Reiterated Rating	Buy	$31.00 ➝ $51.00	High
11/5/2018	SunTrust Banks	Boost Price Target	Buy ➝ Reduce	$30.00	Low
11/2/2018	HC Wainwright	Reiterated Rating	Buy ➝ Positive	$31.00	Medium
11/2/2018	Citigroup	Downgrade	Buy ➝ Neutral	$25.00 ➝ $28.00	Medium
11/1/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	High
10/16/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $25.00	High
10/5/2018	Cantor Fitzgerald	Boost Price Target		$15.00 ➝ $35.00	Medium
9/25/2018	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $15.00	Low
9/25/2018	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $20.00	High
9/25/2018	Citigroup	Boost Price Target	Buy ➝ Reduce	$5.00 ➝ $17.00	High
9/24/2018	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Buy	$10.00	High
9/12/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	Medium
8/23/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	High
8/1/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	High
7/18/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	High
6/12/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	Medium
5/30/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	High
5/24/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	Low
5/14/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	High
5/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	Low
4/12/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	Low
4/4/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	High
3/12/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	Low
3/1/2018	HC Wainwright	Reiterated Rating	Buy		Low
2/27/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	Medium
2/16/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	Low
1/23/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	High
1/4/2018	Cantor Fitzgerald	Set Price Target	Buy	$10.00	High
12/19/2017	Cantor Fitzgerald	Set Price Target	Buy	$10.00	High
12/13/2017	Cantor Fitzgerald	Set Price Target	Buy	$10.00	Low
12/6/2017	Cantor Fitzgerald	Set Price Target	Buy	$10.00	High
11/13/2017	Cantor Fitzgerald	Set Price Target	Buy	$10.00	N/A
11/2/2017	HC Wainwright	Reiterated Rating	Buy	$10.00	N/A
11/1/2017	Cantor Fitzgerald	Set Price Target	Buy	$10.00	N/A
10/11/2017	Jefferies Financial Group	Reiterated Rating	Buy		N/A
9/26/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	Low
9/14/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	High
8/29/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	Low
8/14/2017	Cantor Fitzgerald	Set Price Target	Buy	$10.00	Medium
8/9/2017	HC Wainwright	Reiterated Rating	Buy	$10.00	Medium
8/3/2017	HC Wainwright	Reiterated Rating	Buy	$10.00	Low
8/3/2017	Jefferies Financial Group	Reiterated Rating	Buy	$7.00	Medium
6/30/2017	Jefferies Financial Group	Boost Price Target	Buy	$5.00 ➝ $7.00	Medium
6/29/2017	Jefferies Financial Group	Initiated Coverage	Buy ➝ Reduce	$7.00 ➝ $3.50	Medium
6/28/2017	HC Wainwright	Reiterated Rating	Buy	$10.00	High
6/26/2017	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$10.00	High
6/12/2017	Cantor Fitzgerald	Set Price Target	Buy	$5.00	Low
6/12/2017	Jefferies Financial Group	Reiterated Rating	Buy	$5.00	Low
6/1/2017	HC Wainwright	Reiterated Rating	Buy	$10.00	Low

(Data available from 5/28/2017 forward)

News Sentiment Rating

0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

17 very positive mentions
30 positive mentions
7 negative mentions
5 very negative mentions

Mentions as of

10/30/2021

15 very positive mentions
37 positive mentions
13 negative mentions
7 very negative mentions

Mentions as of

11/29/2021

6 very positive mentions
9 positive mentions
3 negative mentions
2 very negative mentions

Mentions as of

12/29/2021

1 very positive mentions
18 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/28/2022

3 very positive mentions
9 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

2/27/2022

4 very positive mentions
8 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

3/29/2022

2 very positive mentions
13 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/28/2022

2 very positive mentions
24 positive mentions
15 negative mentions
1 very negative mentions

Mentions as of

5/28/2022

Current Sentiment

Recent Stories by Sentiment

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Today's Range

Now: $1.44

$1.36

$1.46

50 Day Range

MA: $2.56

$1.13

$3.69

52 Week Range

Now: $1.44

$1.11

$5.97

Volume

1,274,907 shs

Average Volume

4,015,122 shs

Market Capitalization

$571.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Amarin?: The following Wall Street sell-side analysts have issued reports on Amarin in the last twelve months: Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Northland Securities, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for AMRN.
What is the current price target for Amarin?: 0 Wall Street analysts have set twelve-month price targets for Amarin in the last year. Their average twelve-month price target is $4.38, suggesting a possible upside of 203.8%.
View the latest price targets for AMRN.
What is the current consensus analyst rating for Amarin?: Amarin currently has 2 sell ratings, 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AMRN, but not buy more shares or sell existing shares.
View the latest ratings for AMRN.
What other companies compete with Amarin?: Other companies that are similar to Amarin include Corcept Therapeutics, Amicus Therapeutics, Mirati Therapeutics, OPKO Health, PTC Therapeutics, Sage Therapeutics, Amphastar Pharmaceuticals, Schrödinger, Turning Point Therapeutics, Emergent BioSolutions, Ironwood Pharmaceuticals, Global Blood Therapeutics, Aurinia Pharmaceuticals, ChemoCentryx and HUTCHMED. Learn More about companies similar to Amarin.
How do I contact Amarin's investor relations team?: Amarin's physical mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company's listed phone number is (531) 669-9020 and its investor relations email address is [email protected] The official website for Amarin is www.amarincorp.com. Learn More about contacing Amarin investor relations.

NASDAQ:AMRN - Amarin Stock Price Target and Predictions

Analyst Price Target for AMRN

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.03 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Amarin?

What is the current price target for Amarin?

What is the current consensus analyst rating for Amarin?

What other companies compete with Amarin?

How do I contact Amarin's investor relations team?